Quantcast
Last updated on April 24, 2014 at 6:16 EDT

Latest Inovio Pharmaceuticals Inc. Stories

2013-08-06 12:26:40

BLUE BELL, Pa., Aug. 6, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in view of the unusual market activity in the company's stock, the Exchange has contacted the company in accordance with its usual practice. The company stated that its policy is not to comment on unusual market activity. About Inovio Pharmaceuticals, Inc. Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its...

2013-07-24 04:22:15

Mice and monkey study demonstrates robust and broad immune responses; T-cells 18-fold greater than next best peer technology induce tumor-killing function and increase rate of survival BLUE BELL, Pa., July 24, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study with two animal models, Inovio's hTERT (human telomerase reverse transcriptase) DNA cancer vaccine administered with Inovio's CELLECTRA(®) adaptive electroporation...

2013-07-18 04:21:31

New application of CELLECTRA® electroporation technology dramatically enhances ability of DNA therapy to stimulate blood vessel growth and recovery from debilitation caused by blocked arteries of the legs BLUE BELL, Pa., July 18, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that the use of its proprietary electroporation technology significantly enhanced the ability of a DNA therapy to stimulate blood vessel growth, which may be beneficial...

2013-07-11 08:34:08

HONG KONG, July 11, 2013 /PRNewswire/ -- Insiderslab.com is has released insider trading report as the following stocks: Green Mountain Coffee Roasters (NASDAQ:GMCR), FedEx (NYSE:FDX), American Tower (NYSE:AMT), Family Dollar Stores (NYSE:FDO), Fifth Third Bancorp (NASDAQ:FITB), and Inovio Pharmaceuticals (NYSEMKT:INO). (Logo: http://photos.prnewswire.com/prnh/20100419/HKM001LOGO ) (Read full report by clicking the link below, you may need to copy and paste the full link to your...

2013-07-10 04:20:44

Next-generation HIV vaccine achieves seven-fold increase (7% to 52%) in response rate of CD8 T-cells when delivered with electroporation; robust CD4 or CD8 T-cell responses observed in 89% of subjects BLUE BELL, Pa., July 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today the peer-reviewed publication of results from two phase I trials (HVTN 070 and HVTN 080) of its PENNVAX(®)-B preventive HIV DNA vaccine delivered with a DNA adjuvant and with or...

2013-07-08 04:21:52

For the first time a vaccine shields animals from sickness and death against the newly emergent H7N9 flu virus; vaccine generates significant levels of T-cells and protective antibodies BLUE BELL, Pa., July 8, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they...

2013-06-20 12:30:24

BLUE BELL, Pa., June 20, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that CEO Dr. J. Joseph Kim will be presenting an overview of the company as part of the Small Cap Breakthrough Technologies Track at the OneMedForum investor conference taking place at the Metropolitan Club in New York City. Inovio's PresentationThursday, June 279:40 a.m. EDT A live and archived webcast of the presentation will be available on Inovio's homepage. About OneMedForum...

2013-06-14 04:20:50

Universal H7N9 vaccine generates protective HAI antibodies against unmatched influenza strain in 100% of tested animals; also shows how quickly Inovio can respond to a pandemic threat BLUE BELL, Pa., June 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of its influenza DNA vaccine against the newly emergent, virulent H7N9 flu virus it achieved immune response levels exceeding what are considered protective levels in...

2013-05-14 08:34:53

Polyvalent Vaccine Design Stimulates Significant Antibody and T-Cell Responses with 100% Survival Against Multiple Families of Most Lethal Virus Known to Man BLUE BELL, Pa., May 14, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of Inovio's SynCon(®) DNA vaccine against Ebola and Marburg filoviruses, labeled "Category A" bioterrorism agents by the U.S. government, the vaccine induced strong and broad immune responses...

2013-05-10 16:25:03

BLUE BELL, Pa., May 10, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) today reported financial results for the quarter ended March 31, 2013. Total revenue was $1.5 million for the three months ended March 31, 2013, compared to $1.7 million for the same period in 2012. Total operating expenses were $8.1 million compared to $5.9 million. The net loss attributable to common stockholders was $8.8 million, or $0.06 per share, compared to $8.3 million, or $0.06 per share....